GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rani Therapeutics Holdings Inc (NAS:RANI) » Definitions » Piotroski F-Score

Rani Therapeutics Holdings (Rani Therapeutics Holdings) Piotroski F-Score : 0 (As of Apr. 25, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rani Therapeutics Holdings Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 0 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rani Therapeutics Holdings has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Rani Therapeutics Holdings's Piotroski F-Score or its related term are showing as below:

During the past 5 years, the highest Piotroski F-Score of Rani Therapeutics Holdings was 4. The lowest was 0. And the median was 4.


Rani Therapeutics Holdings Piotroski F-Score Historical Data

The historical data trend for Rani Therapeutics Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rani Therapeutics Holdings Piotroski F-Score Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 4.00 - -

Rani Therapeutics Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -8.372 + -9.303 + -9.197 + -7.098 = $-33.97 Mil.
Cash Flow from Operations was -12.154 + -12.301 + -14.303 + -12.478 = $-51.24 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(108.027 + 96.446 + 83.507 + 70.436 + 57.916) / 5 = $83.2664 Mil.
Total Assets at the begining of this year (Dec22) was $108.03 Mil.
Long-Term Debt & Capital Lease Obligation was $24.48 Mil.
Total Current Assets was $50.85 Mil.
Total Current Liabilities was $7.99 Mil.
Net Income was -6.223 + -7.624 + -7.955 + -8.786 = $-30.59 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(124.207 + 115.309 + 104.344 + 108.202 + 108.027) / 5 = $112.0178 Mil.
Total Assets at the begining of last year (Dec21) was $124.21 Mil.
Long-Term Debt & Capital Lease Obligation was $29.21 Mil.
Total Current Assets was $100.92 Mil.
Total Current Liabilities was $4.82 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rani Therapeutics Holdings's current Net Income (TTM) was -33.97. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rani Therapeutics Holdings's current Cash Flow from Operations (TTM) was -51.24. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-33.97/108.027
=-0.31445842

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-30.588/124.207
=-0.24626631

Rani Therapeutics Holdings's return on assets of this year was -0.31445842. Rani Therapeutics Holdings's return on assets of last year was -0.24626631. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Rani Therapeutics Holdings's current Net Income (TTM) was -33.97. Rani Therapeutics Holdings's current Cash Flow from Operations (TTM) was -51.24. ==> -51.24 <= -33.97 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=24.484/83.2664
=0.29404418

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=29.208/112.0178
=0.26074427

Rani Therapeutics Holdings's gearing of this year was 0.29404418. Rani Therapeutics Holdings's gearing of last year was 0.26074427. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=50.847/7.989
=6.36462636

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=100.924/4.815
=20.96033229

Rani Therapeutics Holdings's current ratio of this year was 6.36462636. Rani Therapeutics Holdings's current ratio of last year was 20.96033229. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Rani Therapeutics Holdings's number of shares in issue this year was 25.88. Rani Therapeutics Holdings's number of shares in issue last year was 24.921. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Rani Therapeutics Holdings's gross margin of this year was . Rani Therapeutics Holdings's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0/108.027
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0/124.207
=0

Rani Therapeutics Holdings's asset turnover of this year was 0. Rani Therapeutics Holdings's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+0+0+0+0+0+0
=0

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rani Therapeutics Holdings has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

Rani Therapeutics Holdings  (NAS:RANI) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Rani Therapeutics Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Rani Therapeutics Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Rani Therapeutics Holdings (Rani Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. The company has developed the RaniPill capsule, a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Executives
Talat Imran director, officer: CEO C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Cone Investments Limited Partnership 10 percent owner AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000
Quiroga Cortes Isidoro Alfonso 10 percent owner 9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759
Jean Luc Butel director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Maulik Nanavaty director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Kate Mckinley officer: CHIEF BUSINESS OFFICER C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Svai S Sanford officer: CFO C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131
Eric Groen officer: General Counsel C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Mir Hashim officer: Chief Scientific Officer C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Lake One Llc 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Aequanimitas Limited Partnership 10 percent owner LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500
Mir A Imran director
Andrew Farquharson director C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Laureen Debuono director
Lisa Ann Rometty director C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131